Ligand Receives $47 Million from WuXi Biologics for Expansion of Worldwide OmniAb® Platform License Agreement
Updates 2018 Full Year and Second Quarter Financial Guidance
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has received $47 million as a result of ...





















